Vascepa, a prescription omega-3 fatty acid, is effective in reducing heart disease risk. The medication reduces inflammation and has helped reduce major adverse cardiovascular events by 25% in patients with high triglycerides and established cardiovascular disease, according to the REDUCE-IT trial. Other studies also found Vascepa reduced the risk of cardiovascular events by 18%. The average cost of Vascepa is around $250 per month.
NCSA Plans Cyber Fraud Insurance Framework
The National Cyber Security Agency (NCSA) is working on a framework for cyber fraud insurance to help manage risks linked to cyberattacks and data breaches.
